Why GHK-Cu Stings: What Formulation Science Says, and What No Trial Has Tested
GHK-Cu, GLOW and KLOW sting is a community staple with no human injection-pain trial. pH, tonicity, benzyl alcohol and copper chemistry, without an injection protocol.
Research use only. This article is scientific background on formulation chemistry and published injection-site-pain research in approved injectables. GHK-Cu, GLOW and KLOW are sold here strictly as laboratory research materials, not for administration to a person or animal. Nothing below is an injection protocol, a site recommendation, a dilution recipe, or medical advice.
TL;DR: the sting question, the evidence, the gap
The question people actually type: why does reconstituted GHK-Cu, and copper blends such as GLOW and KLOW, burn at the injection site more than BPC-157 or TB-500 alone? What exists in the literature: no human trial, and no animal study we could locate, has injection-site pain, sting, burn, redness or a lump as a monitored endpoint for GHK-Cu or those blends. That absence is the finding, not a green light. What does exist: formulation science on subcutaneous injectables in general. Solution pH away from ~7.4, buffer type and strength, osmolality, and preservatives including 0.9% benzyl alcohol all change injection-site pain in controlled studies of other products (PMID 33942212, PMID 36263321, PMID 31587143). What vendor blogs add: four popular mechanisms (net charge, free copper, pH mismatch, hypertonicity), plus site-and-speed recipes. The chemistry is plausible. The percentages, “wasp sting” rankings and “fix it in 20 seconds” claims are not in any GHK-Cu paper. What to do with a vial you bought for research: check the batch CoA and the diluent pH. Our own earlier bacteriostatic-water batch measured pH 3.8, below the USP floor of 4.5. That is a documented failure mode for sting that has nothing to do with copper.
Naturally occurring copper tripeptide complex for skin regeneration and anti-aging research. Stimulates collagen synthesis, accelerates wound healing, and modulates 4000+ genes. Plasma levels decline with age, making it a key target in longevity research.
3-in-1 skin peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg. Targets collagen synthesis, tissue regeneration, and skin repair for comprehensive dermatological research.
4-in-1 anti-aging peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg. Targets collagen synthesis, tissue regeneration, skin repair, and anti-inflammatory pathways.
USP-grade sterile water with 0.9% benzyl alcohol (near-neutral, pH 6.2 to 6.4) - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.
Mitochondrial function, NAD+ metabolism, telomere maintenance
Bacteriostatic water and research supplies
The question the papers never asked
In a 12-month harvest of peptide-forum questions we catalogued in August 2026 (r/Retatrutide, r/Biohackers, r/Peptides, r/Semaglutide and adjacent boards, 87,002 question posts), injection-site sting for GHK-Cu, alone or inside a GLOW or KLOW blend, was among the most frequent practical GHK questions. That harvest is an internal content audit, not a published epidemiology study: it is unrepresentative, the product identity behind any self-report is unknown, and it cannot establish incidence. It is useful only as a map of what people ask.
The published GHK-Cu literature is almost entirely about something else. The 1988 fibroblast paper that still anchors the collagen story added GHK-Cu to cultured cells, not under skin (PMID 3169264). The cleanest in-vivo collagen data is a 1993 rat wound-chamber study with sequential injections into an implanted chamber, measuring dry weight, DNA, protein, collagen and glycosaminoglycans, not nociception (PMID 8227353). Human skin-appearance work used topical creams (PMID 16847171). The 2018 gene-expression review that marketing pages quote is a Connectivity Map analysis, not an injection-tolerability trial (PMID 29986520). The 2022 mouse study people cite for chronic dosing is a cigarette-smoke emphysema model: GHK-Cu was given intraperitoneally at 0.2, 2 and 20 microgram per gram per day on alternate days across 12 weeks of smoke exposure, with lung morphology, inflammation and oxidative-stress readouts and no injection-site-pain scale (PMID 35936787).
Cosmetic-ingredient safety data exists for topical Copper Tripeptide-1 at typical cream concentrations, generally below 10 ppm (Int J Toxicol 2018;37(3_suppl):90S-102S). Read it carefully: the panel's safety conclusion for the copper tripeptide rests on negative irritation and sensitization data, and the single mild-erythema case in the report (1 of 14 subjects) was recorded for the manganese salt of the same tripeptide, not for the copper complex. That is not an injectable dataset, and it is not GLOW or KLOW.
So the first honest sentence is: nobody has published a GHK-Cu injection-site-pain trial. Community frequency is not a rate. “It always burns, so it is real GHK-Cu” is not a quality test. “It did not burn, so it is underdosed” is not a quality test either.
This is not an injection guide
We do not give injection site, needle gauge, angle, speed, volume, warming, icing, lidocaine, or rotation instructions for GHK-Cu, GLOW or KLOW, because these materials are sold for in-vitro and laboratory research, not for administration to a person or animal. Vendor pages that do publish those recipes are selling a use we do not. The papers cited below are about approved injectables and general formulation matrices, not a protocol for a research vial.
What actually makes a subcutaneous injection sting
The useful literature is not about copper peptides. It is about why any aqueous subcutaneous injection hurts.
A 2019 review of subcutaneous injection pain listed needle features, site, volume, injection speed, osmolality, viscosity, pH, buffers and preservatives as the documented levers (Usach et al., Adv Ther 2019, PMID 31587143). Target figures in that review: isotonic around 300 mOsm/kg, keep osmolality under about 600 mOsm/kg, keep pH close to physiological, keep phosphate buffers at or below 10 mM and citrate below 7.3 mM if used at all. Among preservatives used in multi-dose peptide and protein products, m-cresol has been reported as more painful than benzyl alcohol or phenol. Those numbers come from growth-hormone and other licensed injectables, not from GHK-Cu.
A 2021 Pharmaceutical Research study went further and treated the formulation matrix itself as the variable (Shi et al., PMID 33942212). Buffer type and concentration, ionic tonicity agent (especially sodium chloride in acidic buffers) and pH interacted. No single villain explained the pain scores. Citrate at 20 mM with mannitol at pH 5.7 was only medium pain because NaCl was absent. Saline without buffer was low pain. The same amount of NaCl in an acidic buffer was not. The authors’ practical list: avoid buffer if the molecule can self-buffer, if a buffer is required pick a lower-pain one at low millimolar strength, minimise NaCl, keep pH as close to neutral as stability allows.
A 2022 Frontiers in Endocrinology review of parenteral growth-hormone products reached the same cluster of variables (Taghizadeh et al., PMID 36263321). Preservatives again: in one paediatric crossover, m-cresol stung more than benzyl alcohol, with no significant difference between 0.9% and 1.5% benzyl alcohol in that specific comparison. The review also notes that benzyl alcohol’s mild local-anaesthetic effect is one proposed reason it sometimes hurts less than m-cresol, which is the opposite of the “BAC water is what burns” slogan on peptide blogs.
None of those papers reconstituted a GHK-Cu research vial. They still bound the chemistry: an acidic, hypertonic, strongly buffered, preservative-containing solution is a known pain matrix in human subcutaneous tissue. A lyophilized copper tripeptide dissolved in USP bacteriostatic water (WFI plus 0.9% benzyl alcohol, labelled pH 5.7, range 4.5 to 7.0 on the Hospira reference product, NDA 018802) carries the preservative and a solution more acidic than tissue. Buffer strength and tonicity of such a reconstituted research vial have never been measured, so the rest of that matrix is assumed rather than known, and whether the copper complex adds a further, peptide-specific nociceptor effect has not been isolated.
What this article did and did not search
PubMed and DailyMed for GHK-Cu / copper tripeptide plus injection-site pain, sting, burn, erythema, nodule, and subcutaneous tolerability: no dedicated human or animal ISP endpoint paper located as of 25 August 2026. Formulation ISP papers were taken from the rhGH and biologic-injectable literature (PMID 31587143, 33942212, 36263321). Community layer: vendor blogs and forum questions. YouTube pages for this topic return no usable transcript, so video titles were not treated as evidence. Vendor names are omitted; the claims are summarised as a class.
Four mechanisms the blogs name, ranked by how well the papers support them
Peptide-vendor blogs in 2026 converge on the same four-part story. The ranking below is about evidence, not about which blog got there first.
1. pH versus interstitial fluid (~7.4). This is the strongest general claim. Acid-sensing ion channels on peripheral neurons fire as local pH falls. Shi 2021 and Usach 2019 both treat pH as a first-order ISP variable. USP bacteriostatic water is specified at 4.5 to 7.0, with the reference labelled value 5.7. A reconstituted GHK-Cu vial inherits that water plus whatever residual acid or buffer is in the lyophilizate. We have measured a bacteriostatic-water batch at pH 3.8 after it left a previous supplier, below the USP floor, which is acidic enough to sting on chemistry grounds alone and to push pH-sensitive peptides out of solution. That incident is documented on our bacteriostatic-water page and in Bacteriostatic vs acetic acid vs sterile water. It is also why we switched supplier and why we now list lots whose certificate reports a measured pH.
2. Osmolality / tonicity. Also well supported in general. Hypertonic subcutaneous injections increase local pain (Usach 2019). A 5 mg, 10 mg or 50 mg lyophilizate in a small reconstitution volume is a concentrated, possibly hypertonic draw. No published osmolality measurement of reconstituted research GHK-Cu was found, so “this vial is 450 mOsm/kg” is a guess, not a certificate.
3. Benzyl alcohol at 0.9%. Mixed, and blogs oversimplify it. The USP multi-dose diluent contains 9 mg/mL benzyl alcohol. In licensed GH products, benzyl alcohol was less painful than m-cresol in the paediatric comparison cited above. A periocular literature review found preserved saline reduced injection pain relative to unpreserved controls, attributed to benzyl alcohol’s local-anaesthetic effect rather than pH (Eye 2022, DOI 10.1038/s41433-021-01925-z). Peptide blogs that say BAC water is 40 to 50% less painful than sterile water, or that 0.9% benzyl alcohol activates TRPV1 like capsaicin, did not cite a GHK-Cu trial for those figures. Treat benzyl alcohol as a documented ISP-relevant preservative with both irritant and anaesthetic literature, not as a unique copper-peptide toxin.
4. Copper ions, net charge, mast-cell degranulation. Plausible, untested in this setting. GHK-Cu is a Cu(II) complex of glycyl-L-histidyl-L-lysine. The 1993 wound-chamber paper showed the copper-free peptide was a poor collagen stimulus compared with the complex (PMID 8227353), which is about matrix synthesis, not nerves. Free Cu2+ is redox-active. Whether reconstituted research vials contain a meaningful free-copper fraction, and whether that fraction fires nociceptors or degranulates mast cells at the volumes people discuss on forums, has not been measured in a published ISP study. “Positively charged molecule disrupts tissue pH” is a blog compression of several different physical chemistry ideas. Charge, pH and copper are not the same variable.
A fifth community story is colour. Reconstituted GHK-Cu is typically blue to blue-violet because of the copper complex. That colour is expected. It is not a sterility test. Cloudiness, specks that do not settle, or a colour shift toward brown or black are different questions; those belong with Why is my peptide cloudy?, not with “it stung, therefore it is real.”
Why GLOW and KLOW get the same complaint
GLOW as sold here is GHK-Cu 50 mg plus BPC-157 10 mg plus TB-500 10 mg. KLOW is that recipe plus KPV 10 mg. The copper peptide is the majority of the milligram mass in both vials. Forum posts that say “Wolverine is fine, GLOW burns” are comparing a blend without GHK-Cu (BPC-157 plus TB-500) to a blend whose largest component is GHK-Cu. That comparison is consistent with copper or with the higher total solids in the same reconstitution volume. It is not a controlled experiment.
No published study has compared injection-site sensation across GHK-Cu, GLOW, KLOW, BPC-157 or TB-500. KPV’s published work is mouse and cell, gut-directed, with no human injection-tolerability data at all (see KPV and intestinal NF-kB / PepT1). BPC-157 and TB-500 have their own evidence problems, covered separately; none of those papers is an ISP trial either.
Facial flushing, a metallic taste, and a small red mark at the puncture are also frequent self-reports on copper-peptide threads. No topical GHK-Cu dataset reports a rate for stinging or erythema either: the cosmetic-ingredient review cited above concluded on negative irritation and sensitization data, and the widely quoted 2018 gene-expression review (PMID 29986520) carries no tolerability data at all. Translating cream irritation into a subcutaneous “wasp sting” is an analogy without a measurement behind it.
Gastric pentadecapeptide (15 amino acids) known for exceptional tissue repair properties. Promotes wound healing, angiogenesis, and cytoprotection across tendons, muscles, gut, and nerves. Over 30 years of preclinical research.
Full-length 43-amino-acid Thymosin Beta-4, a naturally occurring repair protein, independently confirmed by a third-party CoA from Janoshik. Promotes cell migration and new blood vessel formation for systemic tissue healing. Especially researched for muscle, tendon, and cardiac repair.
Anti-inflammatory tripeptide derived from alpha-MSH (positions 11-13). Inhibits NF-kB signaling, supports gut barrier integrity, and shows antimicrobial activity. A targeted approach to inflammation research without broad immunosuppression.
The Wolverine Stack: BPC-157 + TB-500 in equal parts in one vial (50/50: 10mg = 5mg each, 20mg = 10mg each). The most researched healing peptide duo for tissue repair, tendon recovery, and systemic regeneration. Batch-specific Janoshik COA.
Sting is one question, a lump is another
Forum threads merge two different things under one complaint. A sting is a sensation during or just after the injection, lasting seconds to minutes. A local injection-site reaction is what is still visible afterwards: redness, a raised welt, a firm nodule under the skin, itching, or a bruise. They can have different causes, and the second is the one people photograph and worry about.
In licensed subcutaneous products these reactions are a counted, separately reported adverse-event category. They are the most commonly reported adverse event in the tesamorelin (Egrifta) program, and administration-site reactions were among the most frequent adverse events in the cagrilintide phase 2 trial (Lancet 2021, PMID 34798060). Those are products with monitored endpoints, protocol-defined severity grades and a denominator.
For GHK-Cu, GLOW and KLOW, none of that exists. No published study reports how often redness, welts, induration or itching occur, how severe they are, or how long they last. So there is no rate to quote and no expected duration to state. Anyone publishing a percentage for a copper-peptide injection reaction is publishing a number without a study behind it.
Three mechanisms are worth keeping apart, because forum posts routinely collapse them into one:
- Needle trauma. A bruise or a pinpoint mark is mechanical and has nothing to do with what was in the syringe.
- An irritant reaction from the formulation matrix. This is the pH, tonicity, buffer and preservative chemistry described above. It is chemistry acting on tissue, not an immune response.
- A hypersensitivity response. Itching, hives spreading beyond the injection site, or swelling elsewhere point to an immune mechanism. No GHK-Cu study has tested for one. Mast-cell degranulation, which vendor blogs name confidently, remains a hypothesis in this setting.
General information, not advice about these materials
In clinical practice, an ordinary local reaction to a subcutaneous injection is distinguished from two situations that are assessed by a doctor: signs of infection (redness that spreads, warmth, fever, discharge, or a site that is worse after 48 hours rather than better) and signs of a systemic allergic response (hives beyond the site, swelling of the lips, face or throat, or difficulty breathing, which is an emergency and a reason to call the local emergency number, 112 across the EU). That is general knowledge about injections in medicine, quoted here because the question is asked constantly and the honest answer is not silence. It is not medical advice, it is not a tolerability statement about GHK-Cu, GLOW or KLOW, and it does not change the fact that these materials are supplied for laboratory research and not for administration to a person or animal.
Does more diluent change the chemistry?
This is the follow-up question in almost every sting thread, so here is what the chemistry does and does not say. Adding reconstitution volume lowers the concentration of dissolved solids proportionally, and a less concentrated solution contributes less to osmolality. Osmolality is one of the documented injection-site-pain variables in licensed products (PMID 31587143, PMID 33942212). That is the chemistry, and it is the whole of what we will say: we publish no reconstitution volumes.
Two things it does not do. It does not raise pH toward physiological: the diluent is the pH source, so adding more of the same water pulls the solution toward that water's own pH, not toward 7.4. And it does not remove a variable, it trades one for another, because injection volume is itself listed as a pain factor in the same subcutaneous-injection review (PMID 31587143).
No study has tested dilution against injection-site pain for GHK-Cu, GLOW or KLOW, so the net effect in these specific solutions is unmeasured. That is where our answer stops: this is solution chemistry, not a recommendation, and we do not publish reconstitution volumes as a comfort measure for materials sold for laboratory research.
What the “how to stop the burn” pages are doing
A cluster of research-chemical and clinic blogs in 2024 to 2026 published near-identical explainers: sting is normal, here is why, here is how to eliminate 80 to 90% of it. They name sites, speeds, reconstitution volumes, warming times and, in some cases, local anaesthetic. Those pages have a commercial interest in keeping the reader injecting. We are not going to reproduce the recipes.
Two scientific points are still worth keeping:
- Technique and volume are ISP variables in licensed products (PMID 31587143). That does not convert a research vial into a medicine, and it does not make a forum protocol a study.
- Diluent quality is a real, checkable variable. pH, benzyl alcohol concentration and endotoxin sit on a CoA or they do not. A vendor PDF that only says “sterile, 0.9% BA” without a measured pH is weaker evidence than a lot-specific number. Pharmacy-grade USP bacteriostatic water (the Hospira reference, NDA 018802) is an FDA-approved drug with a legal batch-release duty. Research-reagent water is not. The recipe can be the same. The enforcement is not. That distinction is already written out in Buy bacteriostatic water.
What you can actually verify on a research vial
Identity and quantity of GHK-Cu on a third-party CoA (HPLC plus mass, lot number that matches the vial). Diluent pH in the USP window, preferably a number, not only pass/fail. Endotoxin if the water manufacturer reports it. None of those tests is an injection-pain score. They are the parts of the sting story that are not folklore.
Match the lot
The CoA lot must match the vial. A Janoshik or manufacturer certificate for “Batch 4” with unlabelled vials does not attach to the bottle in your hand. Verification codes on Janoshik reports can be checked at the lab’s own verify page. See How to verify a Janoshik peptide CoA.
Read identity, not colour
For GHK-Cu you want the peptide identified (mass) and quantified (mg in the vial, HPLC purity). Blue colour after reconstitution is the copper complex, not a purity assay. GLOW and KLOW CoAs should break out components, not only a combined vial weight.
Read the water
On a bacteriostatic-water certificate, the fields that carry information are benzyl alcohol content (0.9% in the USP reference), pH against the 4.5 to 7.0 window, sterility and endotoxin. A certificate that omits a measured pH tells you less than one that reports it. The lots we list publish appearance, pH, sterility and endotoxin.
Do not use sting as a quality test
No paper validates “it burned, therefore it is genuine GHK-Cu.” Acidic water, hypertonic draws, benzyl alcohol and needle trauma can sting without any copper in the vial. The inverse is also false: a comfortable draw does not prove the milligram claim on the label.
What this means if you are buying research material in the EU
Injectable GHK-Cu is not an approved medicine in the EU or the US. Topical Copper Tripeptide-1 has a cosmetic-ingredient safety conclusion. GHK-Cu has not been before the FDA's Pharmacy Compounding Advisory Committee at all: a second meeting covering LL-37, GHK-Cu, melanotan II, dihexa acetate and PEG-MGF is expected before the end of February 2027, and that is a US 503A compounding procedure, not an approval, covered in FDA peptide vote, complete results. It does not change how a research vial may be sold in Europe.
If the practical question is route of evidence for skin, that is a different article: the injectable collagen data is rodent, the human appearance data is topical (GHK-Cu topical vs injectable). If the practical question is cloudy reconstituted peptide, start with pH and temperature, not with copper folklore (Why is my peptide cloudy?).
Copper peptide on its own
Naturally occurring copper tripeptide complex for skin regeneration and anti-aging research. Stimulates collagen synthesis, accelerates wound healing, and modulates 4000+ genes. Plasma levels decline with age, making it a key target in longevity research.
USP-grade sterile water with 0.9% benzyl alcohol (near-neutral, pH 6.2 to 6.4) - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.
Copper plus repair peptides
3-in-1 skin peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg. Targets collagen synthesis, tissue regeneration, and skin repair for comprehensive dermatological research.
4-in-1 anti-aging peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg. Targets collagen synthesis, tissue regeneration, skin repair, and anti-inflammatory pathways.
Same stack, no GHK-Cu
The Wolverine Stack: BPC-157 + TB-500 in equal parts in one vial (50/50: 10mg = 5mg each, 20mg = 10mg each). The most researched healing peptide duo for tissue repair, tendon recovery, and systemic regeneration. Batch-specific Janoshik COA.
Gastric pentadecapeptide (15 amino acids) known for exceptional tissue repair properties. Promotes wound healing, angiogenesis, and cytoprotection across tendons, muscles, gut, and nerves. Over 30 years of preclinical research.
Full-length 43-amino-acid Thymosin Beta-4, a naturally occurring repair protein, independently confirmed by a third-party CoA from Janoshik. Promotes cell migration and new blood vessel formation for systemic tissue healing. Especially researched for muscle, tendon, and cardiac repair.
Sources
- Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PMID 3169264. https://pubmed.ncbi.nlm.nih.gov/3169264/
- Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993. PMID 8227353. https://pubmed.ncbi.nlm.nih.gov/8227353/
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. PMID 29986520. https://pubmed.ncbi.nlm.nih.gov/29986520/
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015. PMID 26236730. https://pubmed.ncbi.nlm.nih.gov/26236730/
- Zhang Q, Yan L, Lu J, Zhou X. Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Front Mol Biosci. 2022;9:925700. PMID 35936787. https://pubmed.ncbi.nlm.nih.gov/35936787/
- Usach I, Martinez R, Festini T, Peris JE. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site. Adv Ther. 2019;36(11):2986-2996. PMID 31587143. https://pubmed.ncbi.nlm.nih.gov/31587143/
- Shi GH, Pisupati K, Parker JG, et al. Subcutaneous Injection Site Pain of Formulation Matrices. Pharm Res. 2021;38(5):779-793. PMID 33942212. https://pubmed.ncbi.nlm.nih.gov/33942212/
- Taghizadeh B, et al. New insight into the importance of formulation variables on parenteral growth hormone preparations: potential effect on the injection-site pain. Front Endocrinol. 2022. PMID 36263321. https://pubmed.ncbi.nlm.nih.gov/36263321/
- Bacteriostatic preserved saline for pain-free periocular injections: review. Eye. 2022. DOI 10.1038/s41433-021-01925-z. https://www.nature.com/articles/s41433-021-01925-z
- DailyMed / Hospira. Bacteriostatic Water for Injection, USP. NDA 018802. pH 5.7 (4.5 to 7.0), 0.9% benzyl alcohol. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87d6e9dc-fe3b-4593-ac9a-d7493d1959c7
- Cosmetic Ingredient Review. Safety Assessment of Tripeptide-1, Hexapeptide-12, their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Oligopeptides. Int J Toxicol. 2018;37(3_suppl):90S-102S.
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259. PMID 16847171. https://pubmed.ncbi.nlm.nih.gov/16847171/
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PMID 34798060. https://pubmed.ncbi.nlm.nih.gov/34798060/
- Li H, Kang L, et al. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res. 2015. PMID 25690343. https://pubmed.ncbi.nlm.nih.gov/25690343/
Research use only. GHK-Cu, GLOW and KLOW are supplied for laboratory research, not for human or animal administration, not as cosmetics, and not as medicines. Nothing in this article is a dosing, injection, or medical instruction.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.